This webcast features: Stewart McNaull, senior vice president of Business Development, KBI Biopharma, Inc.
With biopharma’s ever-evolving pipeline of novel protein therapeutics, such as bi-specific antibodies, multimeric proteins, Fc-fusion proteins, and advanced monoclonal antibodies, CHO cells are being pushed to their productivity limits in drug development and manufacturing. Biopharmaceutical companies working on these promising new therapies increasingly struggle with development challenges such as weak protein expression, low-yield purification steps, and poorly optimized analytical techniques. As innovators address these challenges, robust cell expression platforms and advanced process, analytical and manufacturing technologies are vital.
KBI Biopharma and Selexis SA have a long history of meeting these challenges through successful collaboration with their client partners. In this endeavor, KBI has performed development and/or manufacturing services using more than 20 different Selexis generated cell lines since 2012. Together, Selexis and KBI create the fastest and most robust “Gene to GMP” service offering in the biopharmaceutical industry.
- Summarizes the cell line, process and analytical technologies used by KBI and Selexis to advance bispecifics, Fc-fusion proteins, biosimilars, and monoclonal antibody products into the clinic.
- Demonstrates Selexis and KBI’s integrated solution for rapid clinical development and GMP supply of the most challenging emerging therapies.